4.7 Letter

Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2

Related references

Note: Only part of the references are listed.
Review Medicine, General & Internal

MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer

John J. O'Shea et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Review Pharmacology & Pharmacy

JAK2 inhibition for the treatment of hematologic and solid malignancies

Brian L. Harry et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)

Article Multidisciplinary Sciences

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

Priya Koppikar et al.

NATURE (2012)

Article Biochemistry & Molecular Biology

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

Oliver Hantschel et al.

NATURE CHEMICAL BIOLOGY (2012)

Article Medicine, General & Internal

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srdan Verstovsek et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Oncology

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

Animesh Pardanani et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Article Medicine, Research & Experimental

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia

Andrea Hoelbl et al.

EMBO MOLECULAR MEDICINE (2010)

Article Multidisciplinary Sciences

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

Mark A. Dawson et al.

NATURE (2009)